Jara-Palomares and colleagues should be congratulated for developing and externally validating an international score to estimate the risk of cancer within one year after venous thromboembolism (VTE) [1]. Their study draws on the RIETE registry and external validation cohorts from COMMAND VTE Registry-2 and the SOME trial, thereby addressing an important gap in the field: how to move beyond the binary question of whether all patients with VTE should undergo extensive cancer screening, and toward a more individualized approach.
